Europe Doubles Down on Peptide Power

Rubicon backs Sweden’s PeptiSystems as Europe accelerates investment in peptide manufacturing to meet rising global demand

18 Nov 2025

Europe’s peptide drug industry is entering a period of expansion, marked by fresh investment in the manufacturing systems needed to produce therapies at commercial scale. The shift reflects growing demand for peptide-based medicines and the infrastructure required to support them.

In November 2025, PeptiSystems, a Sweden-based developer of peptide manufacturing technologies, secured growth equity from Rubicon Healthcare Partners. Financial terms were not disclosed. According to company statements, the investment is intended to accelerate the company’s expansion as global interest in peptide therapeutics increases.

Peptide drugs are used to treat metabolic diseases, cancer and endocrine disorders, among other conditions. Market research points to sustained growth in the global peptide therapeutics sector, a trend that is placing new pressure on manufacturers to expand production while complying with stringent regulatory standards. In Europe, where life sciences companies are seeking to strengthen regional supply chains, that demand has translated into increased attention to advanced manufacturing capabilities.

PeptiSystems focuses on helping pharmaceutical and biotechnology companies move from early-stage development to commercial-scale production. Its technologies are designed to address what industry executives often describe as a bottleneck: the difficulty of scaling peptide synthesis efficiently and reliably as more drug candidates advance through clinical development.

Following the transaction, Rubicon Healthcare Partners will become PeptiSystems’ largest shareholder. The Nordic life sciences investor has emphasized the strategic importance of enabling technologies for peptide and oligonucleotide manufacturing, citing rising global demand for both modalities.

Industry analysts increasingly describe manufacturing capacity as a competitive differentiator. As more peptide drugs progress into late-stage trials, companies are weighing not only scientific innovation but also the reliability and resilience of supply. Large pharmaceutical manufacturers active in peptide-related therapies have shown that sustained investment in production infrastructure can bolster supply security and market position.

Regulatory complexity and intensifying competition among technology providers remain challenges. Yet the PeptiSystems deal signals that investors are looking beyond drug discovery alone, placing greater value on the systems that bring peptide medicines to patients at scale. That focus could shape Europe’s role in the sector’s next phase of growth.